A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.
about
New treatment strategies for hepatitis C infectionProspects for nucleic acid-based therapeutics against hepatitis C virusTargeted inhibition of the hepatitis C internal ribosomal entry site genomic RNA with oligonucleotide conjugatesIn vitro inhibition of hepatitis C virus by antisense oligonucleotides in PBMC compared to hepatoma cells.Optimized high-throughput screen for hepatitis C virus translation inhibitors.The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit.Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.New treatments for chronic hepatitis C.Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection.Targets of emerging therapies for viral hepatitis B and C.Gene therapy for viral hepatitis.New therapeutic opportunities for hepatitis C based on small RNA.Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.New drugs for hepatitis C virus.Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.Unmasking the information encoded as structural motifs of viral RNA genomes: a potential antiviral target.Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.Injection site reactions after subcutaneous oligonucleotide therapyThe therapeutic potential of new investigational hepatitis C virus translation inhibitors.Hepatitis C virus replication and potential targets for direct-acting agents.HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies
P2860
Q26795407-50DA1C5F-FB55-4F50-8BB9-1A36BA536191Q26852368-0E635E87-8E2E-4B86-8AD5-BAFCFF8B399EQ27485045-7AF7149C-83BC-4459-B103-61508E8DA0B2Q33759357-DE807FEA-67EA-4BC8-8BF8-AE965CCFDD65Q33812679-4406DBA5-335B-4798-BA48-309B91D7980CQ34002207-4A71952C-EF92-4540-A093-43FE42877783Q34038589-FBDF52B9-7948-4E61-BB8F-DD39B130B93CQ34409020-F5A4B81F-A124-409C-96F7-4DB47E573535Q35833006-E8C7B5EE-4751-4AEA-87FF-5696964EC712Q36072471-DCEABF23-5FDC-4548-B4C6-2C15E0CB9627Q36505483-777BCD0B-3D45-49AA-B2D6-36D3425B7FA9Q36653655-C9E95D69-1445-4846-B9AF-2D2CE2AAE088Q36708296-387D9A09-B00B-41E8-A2F5-F09F30B2F955Q36921336-10F7EE25-D7A1-4CB3-A7E2-4C4A35D72D4DQ37321859-AAF9EFBF-44B9-4603-8D8C-6E7DF8FD3E34Q37346061-0F3D3284-AC11-4B08-897B-ADE4808364FFQ37419563-C4FA8D57-6C6E-48AC-8E85-573BC07285DDQ38132094-5E72E223-66B3-49C8-8823-57053B39079CQ38335830-A1A466CA-DC46-49B9-9E1A-4B85C8A0B18DQ38803235-A0242A1E-84C3-4FE6-A701-6B3082486F01Q38930861-6335A730-D175-4AA7-A58D-A7E1FEFA1AA4Q39802266-DA8F1DF1-8582-427F-BA1B-A2796CD5ECFCQ57168365-836CE968-A5D8-4B99-B051-A4B4C8419652
P2860
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A phase I trial of an antisens ...... chronic hepatitis C patients.
@en
A phase I trial of an antisens ...... chronic hepatitis C patients.
@nl
type
label
A phase I trial of an antisens ...... chronic hepatitis C patients.
@en
A phase I trial of an antisens ...... chronic hepatitis C patients.
@nl
prefLabel
A phase I trial of an antisens ...... chronic hepatitis C patients.
@en
A phase I trial of an antisens ...... chronic hepatitis C patients.
@nl
P2093
P1476
A phase I trial of an antisens ...... chronic hepatitis C patients.
@en
P2093
F Andrew Dorr
John G McHutchison
Keyur Patel
Lisa Nyberg
Paul Pockros
Rosie Z Yu
Stephen Pianko
T Jesse Kwoh
P356
10.1016/J.JHEP.2005.09.009
P577
2005-10-25T00:00:00Z